Overview

A Clinical Study of Tranilast in the Treatment of Scleredema Diabeticorum

Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
0
Participant gender:
All
Summary
56 patients with scleredema diabeticorum will be selected to receive treatment of tranilast. After a period of time ,we can determine the efficacy of the drug by detecting the the thickness of skin before and after treatment.
Phase:
Early Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Treatments:
Tranilast
Criteria
Inclusion Criteria:

- (1)Clinical and histopathological examination has been proved to be scleredema
diabeticorum; (2)Ultrasound and magnetic resonance detection found that the thickest
skin of the back was more than 5mm.

Exclusion Criteria:

- (1)with a liver or kidney disease, or accompanied by a tumor or a severe infection ;
(2)Poor blood sugar control; (3)with mental disease.